Skip to main content
HR

Hari Ramachandra

3episodes
1podcast

Featured On 1 Podcast

All Appearances

3 episodes

AI Summary

→ WHAT IT COVERS Stig Brodersen, Tobias Carlisle, and Hari Ramachandra each pitch one stock in this Q1 2026 mastermind session: Berkshire Hathaway during its CEO transition to Greg Abel, Moody's credit rating duopoly at a 22% discount, and BellRing Brands protein drinks trading at an 11% free cash flow yield after an 80% price collapse. → KEY INSIGHTS - **Berkshire Valuation Framework:** Break Berkshire into two buckets — operating businesses (apply ~17x multiple to ~$40B normalized earnings = $680B) plus net equities and cash (~$500B) minus debt. This back-of-envelope method produces ~$550 intrinsic value per B-share against a ~$497 trading price, suggesting roughly fair value with ~10% expected annual returns going forward under Greg Abel. - **Greg Abel Compensation Structure:** Abel receives a $25M flat base salary with no bonuses or stock options, compared to Oracle's CEO at $138M for a company half Berkshire's size. He purchased ~$170M in Berkshire shares personally. Tobias Carlisle argues a more aligned structure would tie compensation to returns above a 6% hurdle rate on capital managed, measured over rolling five-year periods to prevent short-termism. - **BellRing Brands Valuation Dislocation:** BRBR traded at $80 in December 2024 and collapsed to $17 — roughly half Tobias Carlisle's estimated intrinsic value of ~$40. At $17, the stock trades at 12x PE, 9x EV/EBITDA, and an 11% free cash flow yield. The likely cause is GLP-1 drug sentiment, not fundamental deterioration. Three customers — Walmart, Costco, and Amazon — represent 74% of sales, which is a concentration risk to monitor. - **Moody's Competitive Moat Assessment:** Moody's and S&P Global jointly control 80% of global credit ratings under NRSRO regulatory status earned over a century. Issuers pay rating fees that are negligible relative to bond offering sizes (Google recently issued $80-100B), enabling 51% operating margins on a capital-light model. The analytics segment (40% of revenue) faces AI disruption risk, but the ratings segment (60% of revenue) is legally protected and unlikely to be deregulated. - **Market Rotation Signal to Watch:** Since Q3 2024, small-cap stocks have begun outperforming large-cap, value has begun outperforming growth, and equal-weight S&P 500 has begun outperforming market-cap-weighted. Tobias Carlisle frames this as a historically normal pattern following technological transition periods — similar to post-nifty-50 (1970s) and post-dot-com (2000-2015) rotations — suggesting deep value and small/mid-cap names may outperform for an extended period. - **Berkshire as Capital Parking Strategy:** For investors running concentrated portfolios who need equity exposure while awaiting better opportunities, Berkshire offers a practical placeholder: lower drawdowns in bear markets, reasonable valuation versus the S&P 500, and the flexibility to trim positions when high-conviction targets sell off. Buffett himself has compared Berkshire's current role to a utility — a wealth-preservation vehicle rather than a wealth-creation vehicle at trillion-dollar scale. → NOTABLE MOMENT Tobias Carlisle points out that Berkshire's massive cash pile may eventually force a policy shift — even a special dividend — because buybacks cannot meaningfully move the needle at trillion-dollar scale, and no single acquisition in a crash would be large enough to deploy the full position. This challenges the long-held no-dividend orthodoxy. 💼 SPONSORS [{"name": "Simple Mining", "url": "https://simplemining.io/preston"}, {"name": "Masterworks", "url": "https://masterworks.com/billionaires"}, {"name": "NetSuite", "url": "https://netsuite.com/study"}, {"name": "Vanta", "url": "https://vanta.com/billionaires"}, {"name": "Shopify", "url": "https://shopify.com/wsb"}, {"name": "Fundrise", "url": "https://fundrise.com/wsb"}] 🏷️ Berkshire Hathaway, Deep Value Investing, Credit Rating Agencies, Consumer Packaged Goods, CEO Compensation, Market Rotation

AI Summary

→ WHAT IT COVERS Stig Brodersen, Tobias Carlisle, and Hari Ramachandra pitch three undervalued stocks: Sanofi (pharmaceuticals), Remitly (digital remittances), and Crocs (footwear). Each presents valuation metrics, competitive advantages, risks, and growth prospects in current market conditions. → KEY INSIGHTS - **Pharmaceutical Value Play:** Sanofi trades at 16x PE with 4.9% dividend yield versus peers at 25x PE, offering wealth preservation with 7-10% annual returns. The company generates recurring vaccine revenue similar to SaaS models, has diversified revenue beyond single blockbuster drugs, and benefits from euro-based operations providing dollar hedge protection. - **Remittance Market Opportunity:** Remitly captures 3% of $2 trillion remittance market with 30%+ revenue growth, 2.24% take rate, and under 12-month customer payback period with 6x lifetime value ratio. The company serves unbanked populations through local payment infrastructure like GCash in Philippines, creating competitive moat against both traditional services and stablecoin alternatives. - **Footwear Turnaround Candidate:** Crocs generates $900 million free cash flow on $4.3 billion market cap (6x earnings), trades at $79 versus $180 peak, and maintains 58% gross margins despite tariff concerns. The company authorized $1.3 billion buyback (25% of market cap) while growing 9% annually with 16% international growth and 64% China expansion. - **Healthcare Sector Dislocation:** Healthcare and pharmaceutical stocks trade at cheapest valuations relative to S&P 500 since 2000, creating opportunities in non-cyclical businesses with consistent cash flows. Capital flows concentrate in AI and Mag Seven stocks, leaving quality healthcare businesses undervalued despite subscription-like revenue models and regulatory moats protecting market positions. - **Fashion Risk Assessment:** Consumer brands like Crocs face faddish demand risk despite strong current metrics, requiring active monitoring rather than buy-and-hold approach. The company previously traded as net-net during fashion downturns, recovered through focusing on core clog product, but recently made $2.5 billion Hey Dude acquisition that required $700 million impairment, raising capital allocation concerns. → NOTABLE MOMENT Brodersen reveals his company uses Wise for international payments despite pitching Remitly, explaining engineers choose products based on merit while finance professionals recognize inferior products often win through regulatory capture, lobbying, and fee complexity rather than pure product quality. 💼 SPONSORS [{"name": "LinkedIn Jobs", "url": "https://linkedin.com/studybill"}, {"name": "AWS AI", "url": "https://aws.com/ai/r-story"}, {"name": "Unchained", "url": "https://unchained.com/preston"}, {"name": "Shopify", "url": "https://shopify.com/wsb"}, {"name": "Vanta", "url": "https://vanta.com/billionaires"}] 🏷️ Value Investing, Pharmaceutical Stocks, Digital Remittances, Consumer Brands, Healthcare Valuation

AI Summary

→ WHAT IT COVERS Stig Brodersen, Tobias Carlisle, and Hari Ramachandra analyze three investment opportunities: Uber's mobility and delivery ecosystem at $190B market cap, Merck's oncology dominance facing Keytruda patent expiration in 2028, and Bath & Body Works' fragrance retail business trading at 7.5x earnings. → KEY INSIGHTS - **Uber's Network Economics:** The company operates a supply-driven two-sided marketplace requiring critical mass of drivers first before demand materializes. This creates strong local network effects that are difficult to disrupt once established at scale, though effects remain city-specific rather than global, requiring market-by-market conquest against local competitors like Grab in Southeast Asia. - **Autonomous Vehicle Integration:** Uber maintains competitive advantages over pure AV players like Waymo through flexible supply management—human drivers can be called during surge periods while AVs require constant capital deployment. The company's matching algorithm technology and ability to offer both human and autonomous options positions it as potential infrastructure partner rather than displacement target for AV manufacturers. - **Merck's Patent Cliff Strategy:** Keytruda generates $29.5B annually (nearly half of Merck's revenue) with 2028 patent expiration creating 3-5% annual revenue decline rather than immediate cliff due to biosimilar competition dynamics. Management pursues subcutaneous delivery extension, $10B Verona acquisition for COPD drugs, and late-stage pipeline development to offset losses by 2032. - **Bath & Body Works Valuation Disconnect:** The company trades at 7.5x earnings and 6.3x price-to-cash flow versus historical 8x average, generating $750M free cash flow (12% yield on market cap). Management reduced share count from 280M to 212M since 2021 peak, demonstrating capital allocation discipline during 40% stock price decline from all-time highs. - **Pharmaceutical Sector Positioning:** Healthcare trades at 25-year valuation lows relative to broader market, similar to late 1990s setup that preceded strong multi-year performance. Merck's 31% operating margin leads pharma industry while trading at 12x earnings versus peer average of 18x, offering 4% dividend yield during valuation normalization period with limited downside risk. → NOTABLE MOMENT Hari describes riding in a Waymo autonomous vehicle in San Francisco, noting the seamless experience with step-by-step parking directions, automatic passenger recognition, and personalized music selection. The technology demonstration convinced him autonomous driving has moved from laboratory concept to scalable product, though distribution and fleet economics remain unresolved competitive factors. 💼 SPONSORS [{"name": "LinkedIn Jobs", "url": "linkedin.com/studybill"}, {"name": "AWS AI", "url": "aws.com/ai/r-story"}, {"name": "Unchained", "url": "unchained.com/preston"}, {"name": "Shopify", "url": "shopify.com/wsb"}, {"name": "Vanta", "url": "vanta.com/billionaires"}] 🏷️ Value Investing, Autonomous Vehicles, Pharmaceutical Patents, Retail Valuation, Network Effects, Capital Allocation

Never miss Hari Ramachandra's insights

Subscribe to get AI-powered summaries of Hari Ramachandra's podcast appearances delivered to your inbox weekly.

Start Free Today

No credit card required • Free tier available